A new research has revealed that an injection of a new experimental drug might be able to reduce heart attacks risks by decreasing cholesterol levels up to 75 per cent when combined with statin.
The findings showed that the drug evolocumab played a crucial role in lowering "bad" cholesterol levels, which is the main cause of maximum heart risks when given with the usual dose of statin, the Daily Express reported.
When the injection of drug is given, every two weeks or monthly, it blocks the substance which obstructs the liver's ability to eliminate cholesterol from the blood.
Julie Ward of the British Heart Foundation said that although the treatment is proving its worth, other factors like quite smoking, eating healthy and moderate exercising also play a vital role in curbing the health risks.
However, the report notified that further comprehensive research on the drug is still required for security and to determine the long term results.
The study results were published in Jama, the Journal of the American Medical Association.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
